Session 3: PSMA Theranostics: The New Age of Prostate Cancer Imaging and Treatment
Thursday, October 28, 2021 | 9:40 AM – 12:00 PM PST
Moderator:
Michael Hofman, MBBS, Peter MacCallum Cancer Centre; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Australia
LuPSMA: The Newest Treatment Class for Advanced Prostate Cancer
Michael Hofman, MBBS, Peter MacCallum Cancer Centre; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Australia
Results from the PRINCE Trial: Testing the Combination of LuPSMA with Pembrolizumab in mCRPC
Shahneen Sandhu, MBBS, Peter MacCallum Cancer Centre, Australia
Targeting Micro-Metastatic Disease with Auger or Alpha Emitters
Ana Kiess, MD, PhD, Johns Hopkins University
The Four Sisters of Terbium: PET & SPECT Imaging and Targeted Alpha- & Beta-Therapy
Cristina Müller, PhD, PD, Paul Scherrer Institute, Switzerland
aPROMISE: An Artificial Intelligence Platform to Assist in Standardizing the Detection, Localization and Quantification of Prostate Cancer in PYLARIFY PSMA Scans
Aseem Anand, PhD, Imaging-Oncology Biomarker, EXINI Diagnostics AB. Sweden (a wholly owned subsidiary of Lantheus Holdings)
Targeting Fibroblast Activation Protein-alpha (FAP) in Prostate Cancer: Is FAP the Next Theranostic Target after PSMA in Prostate Cancer?
Andy Simmons, PhD, Clovis Oncology
Insights & Future Predictions from 25 Years of PSMA Research
Neil Bander, MD, Weill Cornell Medical College